Back to Journals » Neurobehavioral HIV Medicine » Volume 5

Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs

Authors Ferrer K, Rakhmanina N

Received 18 October 2012

Accepted for publication 20 December 2012

Published 22 January 2013 Volume 2013:5 Pages 1—10

DOI https://doi.org/10.2147/NBHIV.S24888

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Kathleen Ferrer,1,2 Natella Rakhmanina1,2

1Department of Pediatrics, George Washington University School of Medicine, Washington, DC, USA; 2Health Sciences Children's National Medical Center, Washington, DC, USA

Abstract: Tenofovir is a widely used antiretroviral medication indicated to treat adults and children infected with HIV. Current guidelines for the management of HIV infection recommend tenofovir disoproxil fumarate (TDF) as a component of the preferred first-line combination antiretroviral therapy. The efficacy, tolerability, prolonged half-life allowing for once-daily administration, and availability as a component of several fixed-dose formulations make TDF an attractive choice for treatment-naive and treatment-experienced HIV-infected patients. TDF is also widely used as a component of postexposure prophylaxis in noninfected individuals. Most importantly, it has been recently approved for use as pre-exposure prophylaxis for noninfected adults and adolescents to reduce the risk of HIV transmission. With increasing use of TDF among adults and children, understanding of the potential for drug-associated side effects is important. This review focuses on the neuropsychiatric effects of tenofovir in adults and children with HIV infection in comparison with other antiretroviral drugs.

Keywords: HIV, tenofovir, neuropsychiatric effects

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Neurodevelopmental delay in pediatric HIV/AIDS: current perspectives

Blokhuis C, Kootstra NA, Caan MW, Pajkrt D

Neurobehavioral HIV Medicine 2016, 7:1-13

Published Date: 13 January 2016

Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity

Panos SE, Hinkin CH, Singer EJ, Thames AD, Patel SM, Sinsheimer JS, Del Re AC, Gelman BB, Morgello S, Moore DJ, Levine AJ

Neurobehavioral HIV Medicine 2013, 5:11-22

Published Date: 19 June 2013

Management issues in HIV-associated neurocognitive disorders

Cysique LA, Bain MP, Lane TA, Brew BJ

Neurobehavioral HIV Medicine 2012, 4:63-73

Published Date: 11 July 2012

Gene expression for HIV-associated dementia and HIV encephalitis in microdissected neurons 1: preliminary analysis

Shapshak P, Duncan R, Duran EM, Farinetti F, Minagar A, Commins D, Rodriguez H, Chiappelli F, Kangueane P, Levine AJ, Singer E, Somboonwit C, Sinnott JT

Neurobehavioral HIV Medicine 2011, 3:53-78

Published Date: 19 July 2011